Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation

Am J Transplant. 2013 Apr;13(4):1110-1111. doi: 10.1111/ajt.12132. Epub 2013 Feb 22.

Authors

M Carbone^{1

2}, G F Mells^{1

2}, G J Alexander², R H Westbrook³, M A Heneghan³, R N Sandford¹, J M Neuberger⁴

Affiliations

¹ Academic Department of Medical Genetics, Cambridge University, Cambridge, UK.
² Division of Gastroenterology and Hepatology, Cambridge University Department of Medicine, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
³ Institute of Liver Studies, King's College Hospital, London, UK.
⁴ Liver Unit, Queen Elizabeth Hospital, University Hospital of Birmingham, Birmingham, UK.

PMID: 23433321
DOI: 10.1111/ajt.12132

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Calcineurin Inhibitors*
Chromatin Immunoprecipitation
Genetic Markers
Genome-Wide Association Study
Humans
Interleukin-12 Subunit p35 / genetics*
Interleukin-2 / metabolism
Liver Cirrhosis, Biliary / diagnosis*
Liver Cirrhosis, Biliary / etiology
Liver Transplantation / adverse effects*
Polymorphism, Single Nucleotide
Proportional Hazards Models
Recurrence
Risk Factors
Signal Transduction

Substances

Calcineurin Inhibitors
Genetic Markers
IL12A protein, human
Interleukin-12 Subunit p35
Interleukin-2

Grants and funding